Literature DB >> 8958211

HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group.

R Veijola1, H Reijonen, P Vähäsalo, E Sabbah, P Kulmala, J Ilonen, H K Akerblom, M Knip.   

Abstract

Familial aggregation of insulin-dependent diabetes mellitus (IDDM) is a common phenomenon, but the reasons behind it are poorly understood. To investigate whether there is heterogeneity between familial and nonfamilial forms of IDDM we compared genetic, immunological, and clinical characteristics of diabetic children with and without an affected first-degree relative in a population-based series of Finnish children with IDDM. The frequencies of HLA-DQB1 genotypes known to be associated with high (DQB1*0302/0201) or moderate (*0302/x) IDDM risk in the Finnish population were increased, while the proportions of DQB1 genotypes associated with low or decreased risk for IDDM were reduced in the 121 familial cases as compared with the 574 nonfamilial cases (32.7 vs. 21.3%, 41.3 vs. 35.9%, 18.3 vs. 31.4%, and 7.7 vs. 11.4%, respectively; P = 0.002). The frequencies and serum concentrations of islet cell antibodies, insulin autoantibodies, and antibodies to the 65-kD isoform of glutamic acid decarboxylase were similar at diagnosis in the familial and nonfamilial cases. The 31 first-affected cases in the multiple case families were younger at diagnosis than the nonfamilial cases (6.9 vs. 8.5 yr; P < 0.05). The 90 second-affected familial cases had less severe metabolic decompensation at diagnosis than either the first-affected familial or nonfamilial cases. In conclusion, familial aggregation of IDDM in Finland is at least partly explained by a higher frequency of IDDM susceptibility genes in families with multiple affected individuals. The lack of differences in autoantibody levels between the familial and nonfamilial cases indicates homogeneity rather than heterogeneity in the pathogenetic process of beta cell destruction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958211      PMCID: PMC507706          DOI: 10.1172/JCI119067

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Childhood onset diabetes--time trends and climatological factors.

Authors:  G Dahlquist; L Mustonen
Journal:  Int J Epidemiol       Date:  1994-12       Impact factor: 7.196

2.  Long-term risk of IDDM in first-degree relatives of patients with IDDM.

Authors:  T Lorenzen; F Pociot; P Hougaard; J Nerup
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

3.  Coxsackie-B-virus-specific IgM responses, complement-fixing islet-cell antibodies, HLA DR antigens, and C-peptide secretion in insulin-dependent diabetes mellitus.

Authors:  G Schernthaner; J E Banatvala; W Scherbaum; J Bryant; M Borkenstein; E Schober; W R Mayr
Journal:  Lancet       Date:  1985-09-21       Impact factor: 79.321

4.  Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.

Authors:  W A Hagopian; C B Sanjeevi; I Kockum; M Landin-Olsson; A E Karlsen; G Sundkvist; G Dahlquist; J Palmer; A Lernmark
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

5.  Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients.

Authors:  H Tillil; J Köbberling
Journal:  Diabetes       Date:  1987-01       Impact factor: 9.461

6.  A nationwide population-based study of the familial aggregation of type 1 (insulin-dependent) diabetes mellitus in Denmark. Danish Study Group of Diabetes in Childhood.

Authors:  F Pociot; K Nørgaard; N Hobolth; O Andersen; J Nerup
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

7.  Predictive value of islet cell and insulin autoantibodies for type 1 (insulin-dependent) diabetes mellitus in a population-based study of newly-diagnosed diabetic and matched control children.

Authors:  M Landin-Olsson; J P Palmer; A Lernmark; L Blom; G Sundkvist; L Nyström; G Dahlquist
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

8.  Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay.

Authors:  J S Petersen; K R Hejnaes; A Moody; A E Karlsen; M O Marshall; M Høier-Madsen; E Boel; B K Michelsen; T Dyrberg
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

9.  HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis. The Pittsburgh IDDM study.

Authors:  M S Eberhardt; D K Wagener; T J Orchard; R E LaPorte; D E Cavender; B S Rabin; R W Atchison; L H Kuller; A L Drash; D J Becker
Journal:  Diabetes       Date:  1985-12       Impact factor: 9.461

Review 10.  A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group.

Authors:  M Karvonen; J Tuomilehto; I Libman; R LaPorte
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

View more
  21 in total

Review 1.  Genetic predisposition to IDDM.

Authors:  S Caillat-Zucman; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Prediabetes in children: natural history, diagnosis, and preventive strategies.

Authors:  Petri Kulmala
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group.

Authors:  P Kulmala; K Savola; J S Petersen; P Vähäsalo; J Karjalainen; T Löppönen; T Dyrberg; H K Akerblom; M Knip
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

4.  An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.

Authors:  I Vermeulen; I Weets; O Costa; M Asanghanwa; K Verhaeghen; K Decochez; J Ruige; K Casteels; J Wenzlau; J C Hutton; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

5.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

6.  Familial type 1 diabetes mellitus - gender distribution and age at onset of diabetes distinguish between parent-offspring and sib-pair subgroups.

Authors:  Yael Lebenthal; Liat de Vries; Moshe Phillip; Liora Lazar
Journal:  Pediatr Diabetes       Date:  2009-12-02       Impact factor: 4.866

7.  Prediction of type 1 diabetes in the general population.

Authors:  Mikael Knip; Sari Korhonen; Petri Kulmala; Riitta Veijola; Antti Reunanen; Olli T Raitakari; Jorma Viikari; Hans K Akerblom
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112

8.  The ethics of type 1 diabetes prediction and prevention research.

Authors:  Lainie Friedman Ross
Journal:  Theor Med Bioeth       Date:  2003

9.  The musculoskeletal effects of diabetes mellitus.

Authors:  Lawrence H Wyatt; Randy J Ferrance
Journal:  J Can Chiropr Assoc       Date:  2006-03

10.  Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.

Authors:  F K Gorus; E V Balti; I Vermeulen; S Demeester; A Van Dalem; O Costa; H Dorchy; S Tenoutasse; T Mouraux; C De Block; P Gillard; K Decochez; J M Wenzlau; J C Hutton; D G Pipeleers; I Weets
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.